Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: SN Compr Clin Med. 2020 May 23;2(6):836–843. doi: 10.1007/s42399-020-00322-z

Figure 7.

Figure 7.

(a) Gadolinium enhanced MR images (Case 2) comparing pre- (I) and post-DepoCyt treatment (II) after completion of the induction phase (cycle 2). After one month of treatment, periventricular enhancement has significantly diminished. (b) MRI 36 weeks after starting ITV DepoCyt in patient (Case# 2). Images (I, II, III) demonstrate a marked decrease in the bihemispheric tumor burden. (c) MRI 4 weeks following termination of ITV DepoCyt in patient (Case# 2).